Non-small cell lung cancer (NSCLC) therapeutics are gaining increasing importance in the treatment of lung cancer which is one of the leading causes of cancer-related deaths globally. NSCLC therapeutics help in inhibiting tumor growth and decreasing tumor size by targeting specific proteins, genes or structures that contribute to cancer growth and progression.

The global non-small cell lung cancer therapeutics market is estimated to be valued at US$ 27252.31 Mn in 2023 and is expected to exhibit a CAGR of 7.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Opportunity:

Targeted therapies provide immense growth opportunities in the non-small cell lung cancer therapeutics market. Targeted therapies are more precise and have fewer side effects than chemotherapy. They work by blocking the growth and spread of cancer by interfering with specific molecules that are involved in the growth, progression, and spread of cancer. The key molecular targets for targeted therapies in NSCLC include proteins overexpressed in cancer cells like EGFR, ALK, ROS1, BRAF etc. The development of novel targeted therapies for new molecular targets is expected to significantly increase patient response rates and survival, thus driving the demand for NSCLC therapeutics.

Porter's Analysis

Threat of new entrants: High capital requirements and regulatory barriers make it difficult for new players to enter the non-small cell lung cancer market.

Bargaining power of buyers: Buyers have moderate bargaining power due to availability of alternative treatment options and need for specialized medical services.

Bargaining power of suppliers: Suppliers have moderate bargaining power due to differing types of drugs and treatments required for non-small cell lung cancer.

Threat of new substitutes: Threat from new substitutes is moderate as novel targeted therapies and immunotherapies are emerging.

Competitive rivalry: High due to extensive research and differing drugs offered by key players.


SWOT Analysis

Strengths: Rising lung cancer incidence, increasing approval of novel targeted therapies and immunotherapies.

Weaknesses: High treatment costs, risk of drug resistance, frequent relapse of the disease.

Opportunities: Growth prospects in emerging markets, combination therapy treatments, targeted drug delivery systems.

Threats: High R&D costs, stringent regulations, safety concerns over newer therapies.


Key Takeaways

The Global Non-Small Cell Lung Cancer Market Size is expected to witness high growth during the forecast period attributed to rising cancer incidence and improving treatment options.

North America is expected to hold the largest share in the global non-small cell lung cancer market during the forecast period owing to the growing incidence of lung cancer cases, developed healthcare infrastructure, and rising healthcare spending in the region. The Asia Pacific region is likely to grow at the fastest pace attributed to growth opportunities in developing economies such as India and China, rising awareness levels, and increasing healthcare investments.

Get More Insights On This Topic: http://medicalinfoblogs.weebly.com/blog/non-small-cell-lung-cancer-therapeutics-is-estimated-to-witness-high-growth-owing-to-opportunity-in-targeted-therapies